Prevalence and Co-prevalence of Comorbidities Among Patients with Type 2 Diabetes Mellitus in the MENA Region: A Systematic Review

Overview

Journal Curr Diabetes Rev

Publisher Bentham Science Publishers

Specialty Endocrinology

Date 2023 Aug 1

PMID 37526192

Authors

Samir Assaad Khalil

Sami Azar

Khadija Hafidh

George Ayad

Mohamed Safwat

Affiliations

Soon will be listed here.

Abstract

Aim: The management of type 2 diabetes mellitus is affected by the presence of comorbidities. This meta-analysis aimed to determine how likely it is for individuals with type 2 diabetes in the Middle East and North Africa (MENA) region to be living with additional chronic health conditions.

Methods: We searched for studies published from January 2010 to December 2020 in the PubMed, Ovid MEDLINE®, Cochrane CENTRAL, Scopus, and Web of Science databases. Studies of adults with type 2 diabetes in the MENA region were included. We performed a random-effects meta-analysis of single proportions to calculate each comorbidity's overall prevalence/coprevalence.

Results: Statistically significant co-prevalence was detected at p < 0.01 for angina (pooled proportion: 0.24, 95% CI: 0.06, 0.49), cerebrovascular accident (pooled proportion: 0.16, 95% CI: 0.08, 0.26), coronary artery disease (pooled proportion: 0.25, 95% CI: 0.16, 0.35), coronary heart disease (pooled proportion: 0.05, 95% CI: 0.01, 0.12), peripheral vascular disease (pooled proportion: 0.19, 95% CI: 0.13, 0.26), hypertension (pooled proportion: 0.56, 95% CI: 0.43, 0.69), renal impairment (pooled proportion: 0.19, 95% CI: 0.10, 0.29), in addition to hyperlipidemia and overweight/ obesity.

Conclusion: There is evidence of co-prevalence of several comorbidities in patients with type 2 diabetes, highlighting the importance of enhancing communication among healthcare professionals to develop the optimal management plan for each patient.

Citing Articles

Multifaceted Analysis of Lactobacillus plantarum DMR14 Reveals Promising Antidiabetic Properties Through In Vivo Assays and Molecular Simulations.

Islam S, Biswas S, Islam M, Biswas J, Dutta A, Mohiuddin G J Cell Mol Med. 2025; 29(2):e70347.

PMID: 39865621 PMC: 11769970. DOI: 10.1111/jcmm.70347.

Prevalence of cataracts in Iran based on the Persian eye cohort study.

Alipour F, Abdi P, Asadigandomani H, Rezakhani M, Moosaie F, Jafari F Sci Rep. 2024; 14(1):31812.

PMID: 39738422 PMC: 11685764. DOI: 10.1038/s41598-024-83080-5.

Comparison of clinical characteristics, microvascular complications and inflammatory markers in type 2 diabetic patients under insulin versus metformin treatment: A cross-sectional study at Karbala Diabetic Center, Iraq.

Mohammed H, Ben Othman R, Alghurabi H, Hussein R, Al-Obaidi Z, Abdesselem H Medicine (Baltimore). 2024; 103(44):e40330.

PMID: 39495998 PMC: 11537605. DOI: 10.1097/MD.0000000000040330.

References

Correa M, Li Y, Kum H, Lawley M . Assessing the Effect of Clinical Inertia on Diabetes Outcomes: a Modeling Approach. J Gen Intern Med. 2018; 34(3):372-378. PMC: 6420509. DOI: 10.1007/s11606-018-4773-3. View

Kalan Farmanfarma K, Ansari-Moghaddam A, Zareban I, Adineh H . Prevalence of type 2 diabetes in Middle-East: Systematic review& meta-analysis. Prim Care Diabetes. 2020; 14(4):297-304. DOI: 10.1016/j.pcd.2020.01.003. View

Pantalone K, Hobbs T, Wells B, Kong S, Kattan M, Bouchard J . Clinical characteristics, complications, comorbidities and treatment patterns among patients with type 2 diabetes mellitus in a large integrated health system. BMJ Open Diabetes Res Care. 2015; 3(1):e000093. PMC: 4513350. DOI: 10.1136/bmjdrc-2015-000093. View

Hussain S, Chowdhury T . The Impact of Comorbidities on the Pharmacological Management of Type 2 Diabetes Mellitus. Drugs. 2019; 79(3):231-242. DOI: 10.1007/s40265-019-1061-4. View

Chung W, Erion K, Florez J, Hattersley A, Hivert M, Lee C . Precision Medicine in Diabetes: A Consensus Report From the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020; 43(7):1617-1635. PMC: 7305007. DOI: 10.2337/dci20-0022. View

. Abridged for Primary Care Providers. Clin Diabetes. 2020; 38(1):10-38. PMC: 6969656. DOI: 10.2337/cd20-as01. View

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009; 339:b2535. PMC: 2714657. DOI: 10.1136/bmj.b2535. View

Stokes T, Tumilty E, Doolan-Noble F, Gauld R . Multimorbidity, clinical decision making and health care delivery in New Zealand Primary care: a qualitative study. BMC Fam Pract. 2017; 18(1):51. PMC: 5382371. DOI: 10.1186/s12875-017-0622-4. View

Valderas J, Gangannagaripalli J, Nolte E, Boyd C, Roland M, Sarria-Santamera A . Quality of care assessment for people with multimorbidity. J Intern Med. 2019; 285(3):289-300. DOI: 10.1111/joim.12881. View

10.

Aggarwal A, Patel P, Lewison G, Ekzayez A, Coutts A, Fouad F . The Profile of Non-Communicable Disease (NCD) research in the Middle East and North Africa (MENA) region: Analyzing the NCD burden, research outputs and international research collaboration. PLoS One. 2020; 15(4):e0232077. PMC: 7185716. DOI: 10.1371/journal.pone.0232077. View

11.

Ogurtsova K, da Rocha Fernandes J, Huang Y, Linnenkamp U, Guariguata L, Cho N . IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017; 128:40-50. DOI: 10.1016/j.diabres.2017.03.024. View

12.

Einarson T, Acs A, Ludwig C, Panton U . Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol. 2018; 17(1):83. PMC: 5994068. DOI: 10.1186/s12933-018-0728-6. View

13.

Aschner P, Gagliardino J, Ilkova H, Lavalle F, Ramachandran A, Mbanya J . Persistent poor glycaemic control in individuals with type 2 diabetes in developing countries: 12 years of real-world evidence of the International Diabetes Management Practices Study (IDMPS). Diabetologia. 2020; 63(4):711-721. PMC: 7054372. DOI: 10.1007/s00125-019-05078-3. View

14.

Wagnew F, Eshetie S, Kibret G, Zegeye A, Dessie G, Mulugeta H . Diabetic nephropathy and hypertension in diabetes patients of sub-Saharan countries: a systematic review and meta-analysis. BMC Res Notes. 2018; 11(1):565. PMC: 6080368. DOI: 10.1186/s13104-018-3670-5. View

15.

Kaze A, Santhanam P, Musani S, Ahima R, Echouffo-Tcheugui J . Metabolic Dyslipidemia and Cardiovascular Outcomes in Type 2 Diabetes Mellitus: Findings From the Look AHEAD Study. J Am Heart Assoc. 2021; 10(7):e016947. PMC: 8174364. DOI: 10.1161/JAHA.120.016947. View

16.

Alharbi N, Almutari R, Jones S, Al-Daghri N, Khunti K, de Lusignan S . Trends in the prevalence of type 2 diabetes mellitus and obesity in the Arabian Gulf States: systematic review and meta-analysis. Diabetes Res Clin Pract. 2014; 106(2):e30-3. DOI: 10.1016/j.diabres.2014.08.019. View

17.

Wallace E, Salisbury C, Guthrie B, Lewis C, Fahey T, Smith S . Managing patients with multimorbidity in primary care. BMJ. 2015; 350:h176. DOI: 10.1136/bmj.h176. View

18.

Ong K, Lee P, Lee E . Patient-centred and not disease-focused: a review of guidelines and multimorbidity. Singapore Med J. 2019; 61(11):584-590. PMC: 8040921. DOI: 10.11622/smedj.2019109. View